What Voyager Therapeutics does

Voyager Therapeutics is a clinical-stage biotechnology company developing gene therapies and neurogenetic medicines for neurological diseases including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Friedreich's ataxia. The company's core technology is the proprietary TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform, an RNA-based screening system for discovering novel AAV capsids that cross the blood-brain barrier following intravenous dosing — demonstrated to deliver greater than 100-fold improved CNS penetration versus AAV9 in non-human primates and to achieve up to 30-fold improved liver de-targeting in mice. The company has identified the ALPL human receptor homolog underlying capsid uptake, strengthening translational confidence. A second proprietary platform, NeuroShuttle, provides non-viral delivery of multiple therapeutic modalities across the blood-brain barrier using receptor-binding molecules.

The pipeline comprises wholly-owned programs VY1706 (tau-silencing gene therapy for Alzheimer's, FDA IND clearance received June 2026 with H2 2026 dosing planned) and VY7523 (anti-tau monoclonal antibody for Alzheimer's), alongside partnered programs with Neurocrine Biosciences (GBA1 gene therapy for Parkinson's; FXN gene therapy for Friedreich's ataxia), Novartis (Huntington's disease, SMA, undisclosed indication), Alexion/AstraZeneca Rare Disease (capsid licensing), and Transition Bio (TDP-43 small molecules for ALS/FTD). Voyager has no approved commercial products and generates all revenue from collaboration agreements — primarily upfront payments, milestone payments, and future royalties on partnered programs. FY2025 collaboration revenue was $40.4M (down from $80.0M in 2024) against a net loss of $119.7M, with a $201.7M cash position providing runway into 2028.

Name

Voyager Therapeutics

Legal name

Voyager Therapeutics, Inc.

Website

https://voyagertherapeutics.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Voyager Therapeutics is a clinical-stage biotechnology company developing gene therapies and monoclonal antibodies for Alzheimer's, Parkinson's, ALS, and other neurological diseases, using its proprietary TRACER AAV capsid platform for blood-brain barrier delivery, and generating revenue through pharmaceutical partnerships with Neurocrine, Novartis, and Alexion.

Ownership category

akta.pro rank

Product category

Neurology Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industries

Neurology/CNS Gene Therapies (HLAAACAH), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• Gene therapy development
• Neurological disease treatments
• AAV capsid discovery
• Blood-brain barrier delivery
• Neurogenetic medicines

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Collaboration Revenue: Revenue from strategic collaborations with pharmaceutical partners including upfront payments, milestone payments, and royalties on future sales. Voyager receives funding from partners to advance shared development programs.
2. Public Offerings: Equity financing through public offerings of shares and pre-funded warrants to raise capital for clinical development and general corporate purposes.
3. Milestone Payments: Potential milestone payments from partnerships, such as the up to $500 million in milestones from the Transition Bio collaboration for TDP-43 program advancement.
4. Royalty Revenue: Future royalty payments based on progress and sales from partnered programs, including Neurocrine Biosciences collaboration for gene therapies targeting neurological diseases.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Voyager Therapeutics is a clinical-stage biotechnology company developing gene therapies and neurogenetic medicines for neurological diseases including Alzheimer's disease, ALS, Parkinson's disease, and Friedreich's ataxia. The company's core offerings are built on its proprietary TRACER AAV capsid discovery platform, which generates novel capsids capable of crossing the blood-brain barrier following intravenous dosing, and its NeuroShuttle non-viral delivery platform. Voyager monetizes these platforms through wholly-owned pipeline programs and strategic collaborations with major pharmaceutical partners (Neurocrine Biosciences, Novartis, Alexion, Transition Bio).

Product overview

Voyager Therapeutics is a biotechnology company developing neurogenetic medicines for neurological diseases. The company's product portfolio includes wholly-owned programs (VY7523 anti-tau antibody and VY1706 tau silencing gene therapy for Alzheimer's disease) built on its proprietary technology platforms. The TRACER™ AAV capsid discovery platform enables novel capsids that cross the blood-brain barrier for gene therapy delivery, while the Voyager NeuroShuttle™ platform provides non-viral delivery of neurotherapeutics. Partnered programs include GBA1 gene therapy for Parkinson's disease, FXN gene therapy for Friedreich's ataxia (with Neurocrine), and TDP-43 small molecules for ALS/FTD (with Transition Bio).

Differentiator

Problem solved

Functional benefit

Products and services

• TRACER AAV Capsid Discovery Platform RNA-based screening platform enabling rapid discovery of AAV capsids with robust blood-brain barrier penetration and enhanced CNS tropism following intravenous dosing. Used to develop gene therapy candidates and licensed to partners such as Alexion.
• Voyager NeuroShuttle Platform Non-viral delivery platform using novel receptor-binding molecules to transport multiple modalities of neurotherapeutics, including monoclonal antibodies and other biologics, across the blood-brain barrier.
• VY1706 Tau Silencing Gene Therapy Wholly-owned gene therapy using a TRACER-derived capsid with vectorized anti-tau siRNA to reduce intracellular tau protein for the treatment of Alzheimer's disease.
• VY7523 Anti-tau Antibody Wholly-owned monoclonal antibody targeting a unique C-terminal tau epitope to block the spread of pathological tau in Alzheimer's disease.
• GBA1 Gene Therapy Program (Parkinson's Disease) Gene therapy program for Parkinson's disease targeting the GBA1 gene, partnered with Neurocrine Biosciences under a January 2023 strategic collaboration that provided $175 million upfront.
• TDP-43 Small Molecule Program (ALS / FTD) Small molecule program targeting TDP-43 for ALS and frontotemporal dementia, partnered with Transition Bio under a November 2025 collaboration with up to $500 million in potential milestones plus royalties.
• NBIB-'223 FXN Gene Therapy (Friedreich's Ataxia) FXN gene therapy program for Friedreich's ataxia partnered with Neurocrine Biosciences, with Voyager retaining an option for 40% US profit share.

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered secondary and core.

• Transition BiosecondaryStrategic or Co-development Partner · 10 November 2025Collaboration to discover and develop small molecules targeting TDP-43 for ALS and frontotemporal dementia. Transition Bio leads discovery and optimization through nomination of a development candidate, after which Voyager may exercise an option for exclusive worldwide rights. Voyager received single-digit million-dollar upfront payment and is eligible for up to $500 million in milestone payments plus royalties.
• Neurocrine BiosciencescoreStrategic or Co-development Partner · 9 January 2023Strategic collaboration to develop gene therapies for neurological diseases, including a GBA1 gene therapy program for Parkinson's disease. Voyager received $175 million upfront and is eligible for milestone payments and royalties based on progress and sales. Neurocrine gained worldwide rights to certain programs while Voyager retains options for profit sharing or milestone/royalty arrangements.
• Novartis Pharma AGcoreStrategic or Co-development PartnerOngoing collaboration with Novartis including three gene therapy programs targeting Huntington's disease, spinal muscular atrophy, and an undisclosed indication. Voyager received funding and maintains certain program rights while Novartis funds development and holds commercialization rights.
• Alexion, AstraZeneca Rare DiseasecoreStrategic or Co-development PartnerCapsid license agreement providing Novartis and Alexion access to Voyager's TRACER-derived capsids for development of gene therapies. Voyager receives upfront payments, option exercise payments, milestones, and royalties, while partners gain validation and potential program use.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• REGENXBIO: AAV gene therapy company with proprietary capsid platform (NAV Technology) for CNS and other indications. Most directly comparable to Voyager on capsid discovery technology and partnered gene therapy programs targeting neurological diseases.
• Denali Therapeutics: Develops therapeutics for neurodegenerative diseases with a proprietary blood-brain barrier delivery platform (ATV platform for both biologics and small molecules). Direct competitor in BBB-penetrant CNS therapeutics with similar target indications including Alzheimer's.
• uniQure: Clinical-stage gene therapy company with AAV-based programs including CNS-focused therapies for Huntington's disease and ALS. Comparable on AAV gene therapy approach for neurological diseases and similar clinical-stage economics with partnership revenue model.
• Wave Life Sciences: Clinical-stage genetic medicines company with oligonucleotide (siRNA/antisense) programs targeting CNS diseases including Huntington's and ALS. Comparable modality overlap with VY1706 (siRNA against tau) and similar focus on neurological indications.
• Taysha Gene Therapies: Clinical-stage AAV gene therapy company focused on CNS diseases and rare monogenic neurological disorders. Comparable pipeline focus (CNS gene therapy, similar clinical-stage profile) and partnership-driven business model.

Broad incumbents

• Sarepta Therapeutics: Established commercial-stage gene therapy company with multiple approved AAV-delivered therapies (Elevidys, etc.) and broad rare disease pipeline. Comparable as a gene therapy developer with established manufacturing and commercialization infrastructure, though focused on neuromuscular rather than CNS.
• BioMarin Pharmaceutical: Commercial-stage biotech with AAV gene therapy (Roctavian for hemophilia A) and significant CNS pipeline including programs for Parkinson's and other neurological conditions. Comparable as AAV gene therapy developer with established regulatory and commercialization capabilities.
• Spark Therapeutics (Roche): Pioneer in AAV gene therapy with approved products (Luxturna) now operating as part of Roche. Comparable AAV gene therapy expertise and CNS pipeline ambitions, with established pharma backing for late-stage development.
• Alnylam Pharmaceuticals: Commercial-stage RNAi therapeutics company with approved siRNA products and programs targeting CNS diseases. Comparable on siRNA delivery science (overlapping technology with VY1706's vectorized anti-tau siRNA approach) and genetic medicines focus.

Emerging players

• Capsida Biotherapeutics: Emerging gene therapy company with proprietary engineered AAV capsid platform for CNS and other tissue targets with reduced liver tropism. Direct competitor in next-generation capsid engineering for neurological disease gene therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/voyager-therapeutics-inc-
• Xx.com/VoyagerTx

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Voyager Therapeutics